Open Innovation Publications & Expert Interviews Archives - Page 23 of 23 - Biowebspin | Biowebspin
Logo Biowebspin
#1 source of information and interviews about academia-industry partneringFollow the latest expert interviews and publications about academia-industry partnering,
technology transfer and licensing in Life Sciences

Open Innovation Publications & Expert Interviews

R&D portfolios and pharmaceutical licensing

R&D portfolios and pharmaceutical licensing

  Biowebspin, August 08th, 2014 R&D portfolios and pharmaceutical licensing by Junichi Nishimura, Yosuke Okada,, inResearch Policy, 2014 We examine how R&D portfolios of drug pipelines affect pharmaceutical licensing, controlling firm size, diversity, and competition. The data collected comprises 434 license-ins and 329 license-outs closed by 54 Japanese pharmaceutical companies between 19... »

Collaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface

Collaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface

  Biowebspin, May 01th, 2014 Collaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface by David M. Andrews, Martin E. Swarbrick, Andrew T. Merritt, in Drug Discovery Today, 2014 In response to the dual challenges of increasingly risky target portfolios and realignment of traditional pharmaceutical company resources away from early-phase research an... »

Current barriers, challenges and opportunities for the development of effective STI vaccines: Point of view of vaccine producers, biotech companies and funding agencies

Current barriers, challenges and opportunities for the development of effective STI vaccines: Point of view of vaccine producers, biotech companies and funding agencies

  Biowebspin, April 01st, 2014 Current barriers, challenges and opportunities for the development of effective STI vaccines: Point of view of vaccine producers, biotech companies and funding agencies by Betty Dodet, in Vaccine, 2014 Several barriers limit the development of vaccines against sexually transmitted diseases (STIs). Critical scientific information is missing that makes the feasibility ... »

Restructuring and innovation in pharmaceuticals and biotechs: The impact of financialisation

Restructuring and innovation in pharmaceuticals and biotechs: The impact of financialisation

  Biowebspin, March 1st, 2014 Restructuring and innovation in pharmaceuticals and biotechs: The impact of financialisation by Pauline Gleadle, Stuart Parris, Alan Shipman, Roberto Simonetti, in Critical Perspectives on Accounting, 2014 In this paper we explore whether a financialisation perspective can provide a more empirically satisfying account of recent developments in the pharmaceutical indus... »

The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?

The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?

  Biowebspin, February 01st, 2015 The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis? by Gavin Giovannoni, David Baker, Klaus Schmierer, in Multiple Sclerosis and Related Disorders, 2015 If it is not feasible to develop licensed drugs to the stage that they can actually be prescribed for a new indication, can we justify, eithe... »

Page 23 of 23«212223